Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Hematologic Improvement-Erythroid (HI-E) rate
Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006)
At 8 weeks of treatment
No
Gail L Brown, MD
Study Director
Telik
United States: Food and Drug Administration
TLK199.2107
NCT01422486
August 2011
October 2013
Name | Location |
---|---|
Columbia University | New York, New York 10032-3784 |
Vanderbilt University | Nashville, Tennessee 37232-6305 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
Loyola University | Maywood, Illinois 60153 |
SIU School of Medicine, Simmons Cancer Center | Springfield, Illinois 62794-9677 |